Viral Inactivation Market Analysis By Product, By Application (Vaccines, Therapeutics, Stem Cell Products, Blood Products, Tissue Products, Cellular, Gene Therapy), By End-use, And Segment Forecasts, 2014 - 2025
The global viral inactivation market is anticipated to reach USD 5.1 billion by 2025, growing at a CAGR of 12.5%, according to a new report by Grand View Research, Inc. Rise in the number of pharmaceutical and biopharmaceutical companies, increase in FDA drug approvals, growth of the life sciences industry, increase in government funding for novel therapies, and drug development are some of the major factors contributing to the growth.
Immense growth has been witnessed in the pharmaceutical and biopharmaceutical industry with a steady rise in the number of companies, drug launches, and new drug discoveries. With an increase in the number of diseases worldwide, the need for new & improved drugs and therapies has been witnessed on a global front. Increase in investment by top players in research and development coupled with the need to find new therapies for the treatment of diseases has contributed to immense growth of pharmaceutical and biopharmaceutical companies, thereby accelerating growth.
Newer drugs are being developed by companies to offer incremental health benefits. Changing lifestyle of people across the globe and adoption of sedentary living habits are primary reasons responsible for the increase in the number of chronic diseases that require drugs and therapies for treatment. According to the FDA, in the year 2014, 41 novel drugs were approved and 45 in the consequent year. This has also been contributing to growth.
Immense funding has been witnessed in the pharmaceutical and biotechnology industries in the recent years. It has been observed that private players are the major contributors for the development of new drugs and therapies, however, there has been increasing government spending on the research and development of new therapies. Increase in funding has also resulted in growth in number of FDA approvals over the recent years. All these factors have been contributing to the immense growth of the market.
Further Key Findings From the Study Suggest:
Immense growth has been witnessed in the pharmaceutical and biopharmaceutical industry with a steady rise in the number of companies, drug launches, and new drug discoveries. With an increase in the number of diseases worldwide, the need for new & improved drugs and therapies has been witnessed on a global front. Increase in investment by top players in research and development coupled with the need to find new therapies for the treatment of diseases has contributed to immense growth of pharmaceutical and biopharmaceutical companies, thereby accelerating growth.
Newer drugs are being developed by companies to offer incremental health benefits. Changing lifestyle of people across the globe and adoption of sedentary living habits are primary reasons responsible for the increase in the number of chronic diseases that require drugs and therapies for treatment. According to the FDA, in the year 2014, 41 novel drugs were approved and 45 in the consequent year. This has also been contributing to growth.
Immense funding has been witnessed in the pharmaceutical and biotechnology industries in the recent years. It has been observed that private players are the major contributors for the development of new drugs and therapies, however, there has been increasing government spending on the research and development of new therapies. Increase in funding has also resulted in growth in number of FDA approvals over the recent years. All these factors have been contributing to the immense growth of the market.
Further Key Findings From the Study Suggest:
- Kits and reagents held the largest share owing to increasing usage of consumables
- Vaccines and therapeutics held the largest share, on the basis of application, and is expected to be the fastest growing segment due to the increased demand for biologics
- The services segment is anticipated to grow at the fastest rate due to increase in the number of pharmaceutical CROs globally
- North America accounted for the largest share owing to presence of dominant players and availability of sophisticated infrastructure along with healthcare reforms to curb the incidence of chronic diseases
- The Asia Pacific region is expected to flourish during the forecast period owing to healthcare reforms and untapped market opportunities in the pharmaceutical industry
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Country Wise Market: Base Estimates
1.2 Global Market: CAGR Calculation
1.3 Region Based Segment Share Calculation
1.4 Research Scope & Assumptions
1.5 List of Data Sources
1.5.1 Data for primary interviews, by sources
1.5.2 Data for primary interviews, by region
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 VIRAL INACTIVATION MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increasing growth of biopharmaceutical and pharmaceutical companies
3.2.2 Rise in the number of new drug launches
3.2.3 Increasing investment in life sciences industries
3.2.4 Rise in government funding for development of biotech and pharma companies
3.2.5 Escalation in chronic diseases leading to increase in healthcare expenditure
3.3 Market Restraint Analysis
3.3.1 High degree of market consolidation
3.4 Market Opportunity Analysis
3.4.1 Growth in pharmaceutical outsourcing industry
3.4.2 Developing countries provide untapped markets for multinational players
3.5 Market Challenges Analysis
3.5.1 Developing countries provide untapped markets for multinational players
3.6 Key Opportunities Prioritized
3.6.1 Key opportunities prioritized, by product
3.6.2 Key opportunities prioritized, by application
3.6.3 Key opportunities prioritized, by end-use
3.7 Viral inactivation - SWOT Analysis, By Factor (political & legal, economic and technological)
3.8 Industry Analysis - Porter’s
3.9 Viral inactivation Market: Market Position Analysis
CHAPTER 4 VIRAL INACTIVATION MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1 Viral inactivation Market: Product Movement Analysis
4.2 Kits and Reagents
4.2.1 Kits and Reagents market, 2014 - 2025 (USD Million)
4.3 Systems
4.3.1 Systems market, 2014 - 2025 (USD Million)
4.4 Services
4.4.1 Services market, 2014 - 2025 (USD Million)
CHAPTER 5 VIRAL INACTIVATION MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1 Viral Inactivation Market: Application Movement Analysis
5.2 Vaccines and Therapeutics
5.2.1 Vaccines and therapeutics market, 2014 - 2025 (USD Million)
5.3 Stem Cell Products
5.3.1 Stem cell products market, 2014 - 2025 (USD Million)
5.4 Blood and Blood Products
5.4.1 Blood and blood products market, 2014 - 2025 (USD Million)
5.5 Tissue and Tissue Products
5.5.1 Tissue and tissue products market, 2014 - 2025 (USD Million)
5.6 Cellular and Gene Therapy
5.6.1 Cellular and gene therapy market, 2014 - 2025 (USD Million)
CHAPTER 6 VIRAL INACTIVATION MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1 Viral Inactivation Market: End-use Movement Analysis
6.2 Pharmaceutical and Biotechnology Companies
6.2.1 Pharmaceutical and biopharmaceutical companies market, 2014 - 2025 (USD Million)
6.3 CROs
6.3.1 CROs market, 2014 - 2025 (USD Million)
6.4 Academic and Research Institutes
6.4.1 Academic and research institutes market, 2014 - 2025 (USD Million)
6.5 Others
6.5.1 Others market, 2014 - 2025 (USD Million)
CHAPTER 7 VIRAL INACTIVATION MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT, APPLICATION, END-USE
7.1 Viral Inactivation Market Share by Region, 2016 & 2025
7.2 North America
7.2.1 North America viral inactivation market, by country, 2014 - 2025 (USD Million)
7.2.2 North America viral inactivation market, by product, 2014 - 2025 (USD Million)
7.2.3 North America viral inactivation market, by application, 2014 - 2025 (USD Million)
7.2.4 North America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.2.5 U.S.
7.2.5.1 U.S. viral inactivation market, by product, 2014 - 2025 (USD Million)
7.2.5.2 U.S. viral inactivation market, by application, 2014 - 2025 (USD Million)
7.2.5.3 U.S. viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.2.6 Canada
7.2.6.1 Canada viral inactivation market, by product, 2014 - 2025 (USD Million)
7.2.6.2 Canada viral inactivation market, by application, 2014 - 2025 (USD Million)
7.2.6.3 Canada viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3 Europe
7.3.1 Europe viral inactivation market, by country, 2014 - 2025 (USD Million)
7.3.2 Europe viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.3 Europe viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.4 Europe viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3.5 Germany
7.3.5.1 Germany viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.5.2 Germany viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.5.3 Germany viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3.6 UK
7.3.6.1 UK viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.6.2 UK viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.6.3 UK viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3.7 France
7.3.7.1 France viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.7.2 France viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.7.3 France viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3.8 Italy
7.3.8.1 Italy viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.8.2 Italy viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.8.3 Italy viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3.9 Spain
7.3.9.1 Spain viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.9.2 Spain viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.9.3 Spain viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific viral inactivation market, by country, 2014 - 2025 (USD Million)
7.4.1.1 Asia Pacific viral inactivation market, by product, 2014 - 2025 (USD Million)
7.4.2 Asia Pacific viral inactivation market, by application, 2014 - 2025 (USD Million)
7.4.3 Asia Pacific viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.4.4 Japan
7.4.4.1 Japan viral inactivation market, by product, 2014 - 2025 (USD Million)
7.4.4.2 Japan viral inactivation market, by application, 2014 - 2025 (USD Million)
7.4.4.3 Japan viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.4.5 China
7.4.5.1 China viral inactivation market, by product, 2014 - 2025 (USD Million)
7.4.5.2 China viral inactivation market, by application, 2014 - 2025 (USD Million)
7.4.5.3 China viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.4.6 India
7.4.6.1 India viral inactivation market, by product, 2014 - 2025 (USD Million)
7.4.6.2 India viral inactivation market, by application, 2014 - 2025 (USD Million)
7.4.6.3 India viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.5 Latin America
7.5.1 Latin America viral inactivation market, by country, 2014 - 2025 (USD Million)
7.5.2 Latin America viral inactivation market, by product, 2014 - 2025 (USD Million)
7.5.3 Latin America viral inactivation market, by application, 2014 - 2025 (USD Million)
7.5.4 Latin America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.5.5 Brazil
7.5.5.1 Brazil viral inactivation market, by product, 2014 - 2025 (USD Million)
7.5.5.2 Brazil viral inactivation market, by application, 2014 - 2025 (USD Million)
7.5.5.3 Brazil viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.5.6 Mexico
7.5.6.1 Mexico viral inactivation market, by product, 2014 - 2025 (USD Million)
7.5.6.2 Mexico viral inactivation market, by application, 2014 - 2025 (USD Million)
7.5.6.3 Mexico viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.6 MEA
7.6.1 MEA viral inactivation market, by country, 2014 - 2025 (USD Million)
7.6.2 MEA viral inactivation market, by product, 2014 - 2025 (USD Million)
7.6.3 MEA viral inactivation market, by application, 2014 - 2025 (USD Million)
7.6.4 MEA viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.6.5 South Africa
7.6.5.1 South Africa viral inactivation market, by product, 2014 - 2025 (USD Million)
7.6.5.2 South Africa viral inactivation market, by application, 2014 - 2025 (USD Million)
7.6.5.3 South Africa viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.6.6 Saudi Arabia
7.6.6.1 Saudi Arabia viral inactivation market, by product, 2014 - 2025 (USD Million)
7.6.6.2 Saudi Arabia viral inactivation market, by application, 2014 - 2025 (USD Million)
7.6.6.3 Saudi Arabia viral inactivation market, by end-use, 2014 - 2025 (USD Million)
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Company Profiles
8.1.1 Danaher Corporation
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2 Merck KGAA
8.1.2.1 Company overview
8.1.2.2 Financial Performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Parker Hannifin Corporation
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Sartorius AG
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5 Rad Source Technologies
8.1.5.1 Company overview
8.1.5.2 Product benchmarking
8.1.6 Viral Inactivated Plasma Systems SA
8.1.6.1 Company overview
8.1.6.2 Product benchmarking
8.1.7 Cerus Corporation
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.8 Clean Cells Inc.
8.1.8.1 Company overview
8.1.8.2 Product benchmarking
8.1.9 Texcell, Inc.
8.1.9.1 Company overview
8.1.9.2 Product benchmarking
8.1.10 Wuxi Pharmatech (Cayman) Inc.
8.1.10.1 Company overview
8.1.10.2 Product benchmarking
8.1.11 Charles River Laboratories
8.1.11.1 Company overview
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives
8.1.12 BioReliance
8.1.12.1 Company overview
8.1.12.2 Product benchmarking
8.1.12.3 Strategic initiatives
8.2 List of market players
1.1 Country Wise Market: Base Estimates
1.2 Global Market: CAGR Calculation
1.3 Region Based Segment Share Calculation
1.4 Research Scope & Assumptions
1.5 List of Data Sources
1.5.1 Data for primary interviews, by sources
1.5.2 Data for primary interviews, by region
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 VIRAL INACTIVATION MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increasing growth of biopharmaceutical and pharmaceutical companies
3.2.2 Rise in the number of new drug launches
3.2.3 Increasing investment in life sciences industries
3.2.4 Rise in government funding for development of biotech and pharma companies
3.2.5 Escalation in chronic diseases leading to increase in healthcare expenditure
3.3 Market Restraint Analysis
3.3.1 High degree of market consolidation
3.4 Market Opportunity Analysis
3.4.1 Growth in pharmaceutical outsourcing industry
3.4.2 Developing countries provide untapped markets for multinational players
3.5 Market Challenges Analysis
3.5.1 Developing countries provide untapped markets for multinational players
3.6 Key Opportunities Prioritized
3.6.1 Key opportunities prioritized, by product
3.6.2 Key opportunities prioritized, by application
3.6.3 Key opportunities prioritized, by end-use
3.7 Viral inactivation - SWOT Analysis, By Factor (political & legal, economic and technological)
3.8 Industry Analysis - Porter’s
3.9 Viral inactivation Market: Market Position Analysis
CHAPTER 4 VIRAL INACTIVATION MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1 Viral inactivation Market: Product Movement Analysis
4.2 Kits and Reagents
4.2.1 Kits and Reagents market, 2014 - 2025 (USD Million)
4.3 Systems
4.3.1 Systems market, 2014 - 2025 (USD Million)
4.4 Services
4.4.1 Services market, 2014 - 2025 (USD Million)
CHAPTER 5 VIRAL INACTIVATION MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1 Viral Inactivation Market: Application Movement Analysis
5.2 Vaccines and Therapeutics
5.2.1 Vaccines and therapeutics market, 2014 - 2025 (USD Million)
5.3 Stem Cell Products
5.3.1 Stem cell products market, 2014 - 2025 (USD Million)
5.4 Blood and Blood Products
5.4.1 Blood and blood products market, 2014 - 2025 (USD Million)
5.5 Tissue and Tissue Products
5.5.1 Tissue and tissue products market, 2014 - 2025 (USD Million)
5.6 Cellular and Gene Therapy
5.6.1 Cellular and gene therapy market, 2014 - 2025 (USD Million)
CHAPTER 6 VIRAL INACTIVATION MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1 Viral Inactivation Market: End-use Movement Analysis
6.2 Pharmaceutical and Biotechnology Companies
6.2.1 Pharmaceutical and biopharmaceutical companies market, 2014 - 2025 (USD Million)
6.3 CROs
6.3.1 CROs market, 2014 - 2025 (USD Million)
6.4 Academic and Research Institutes
6.4.1 Academic and research institutes market, 2014 - 2025 (USD Million)
6.5 Others
6.5.1 Others market, 2014 - 2025 (USD Million)
CHAPTER 7 VIRAL INACTIVATION MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT, APPLICATION, END-USE
7.1 Viral Inactivation Market Share by Region, 2016 & 2025
7.2 North America
7.2.1 North America viral inactivation market, by country, 2014 - 2025 (USD Million)
7.2.2 North America viral inactivation market, by product, 2014 - 2025 (USD Million)
7.2.3 North America viral inactivation market, by application, 2014 - 2025 (USD Million)
7.2.4 North America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.2.5 U.S.
7.2.5.1 U.S. viral inactivation market, by product, 2014 - 2025 (USD Million)
7.2.5.2 U.S. viral inactivation market, by application, 2014 - 2025 (USD Million)
7.2.5.3 U.S. viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.2.6 Canada
7.2.6.1 Canada viral inactivation market, by product, 2014 - 2025 (USD Million)
7.2.6.2 Canada viral inactivation market, by application, 2014 - 2025 (USD Million)
7.2.6.3 Canada viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3 Europe
7.3.1 Europe viral inactivation market, by country, 2014 - 2025 (USD Million)
7.3.2 Europe viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.3 Europe viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.4 Europe viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3.5 Germany
7.3.5.1 Germany viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.5.2 Germany viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.5.3 Germany viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3.6 UK
7.3.6.1 UK viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.6.2 UK viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.6.3 UK viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3.7 France
7.3.7.1 France viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.7.2 France viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.7.3 France viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3.8 Italy
7.3.8.1 Italy viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.8.2 Italy viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.8.3 Italy viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.3.9 Spain
7.3.9.1 Spain viral inactivation market, by product, 2014 - 2025 (USD Million)
7.3.9.2 Spain viral inactivation market, by application, 2014 - 2025 (USD Million)
7.3.9.3 Spain viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific viral inactivation market, by country, 2014 - 2025 (USD Million)
7.4.1.1 Asia Pacific viral inactivation market, by product, 2014 - 2025 (USD Million)
7.4.2 Asia Pacific viral inactivation market, by application, 2014 - 2025 (USD Million)
7.4.3 Asia Pacific viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.4.4 Japan
7.4.4.1 Japan viral inactivation market, by product, 2014 - 2025 (USD Million)
7.4.4.2 Japan viral inactivation market, by application, 2014 - 2025 (USD Million)
7.4.4.3 Japan viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.4.5 China
7.4.5.1 China viral inactivation market, by product, 2014 - 2025 (USD Million)
7.4.5.2 China viral inactivation market, by application, 2014 - 2025 (USD Million)
7.4.5.3 China viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.4.6 India
7.4.6.1 India viral inactivation market, by product, 2014 - 2025 (USD Million)
7.4.6.2 India viral inactivation market, by application, 2014 - 2025 (USD Million)
7.4.6.3 India viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.5 Latin America
7.5.1 Latin America viral inactivation market, by country, 2014 - 2025 (USD Million)
7.5.2 Latin America viral inactivation market, by product, 2014 - 2025 (USD Million)
7.5.3 Latin America viral inactivation market, by application, 2014 - 2025 (USD Million)
7.5.4 Latin America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.5.5 Brazil
7.5.5.1 Brazil viral inactivation market, by product, 2014 - 2025 (USD Million)
7.5.5.2 Brazil viral inactivation market, by application, 2014 - 2025 (USD Million)
7.5.5.3 Brazil viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.5.6 Mexico
7.5.6.1 Mexico viral inactivation market, by product, 2014 - 2025 (USD Million)
7.5.6.2 Mexico viral inactivation market, by application, 2014 - 2025 (USD Million)
7.5.6.3 Mexico viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.6 MEA
7.6.1 MEA viral inactivation market, by country, 2014 - 2025 (USD Million)
7.6.2 MEA viral inactivation market, by product, 2014 - 2025 (USD Million)
7.6.3 MEA viral inactivation market, by application, 2014 - 2025 (USD Million)
7.6.4 MEA viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.6.5 South Africa
7.6.5.1 South Africa viral inactivation market, by product, 2014 - 2025 (USD Million)
7.6.5.2 South Africa viral inactivation market, by application, 2014 - 2025 (USD Million)
7.6.5.3 South Africa viral inactivation market, by end-use, 2014 - 2025 (USD Million)
7.6.6 Saudi Arabia
7.6.6.1 Saudi Arabia viral inactivation market, by product, 2014 - 2025 (USD Million)
7.6.6.2 Saudi Arabia viral inactivation market, by application, 2014 - 2025 (USD Million)
7.6.6.3 Saudi Arabia viral inactivation market, by end-use, 2014 - 2025 (USD Million)
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Company Profiles
8.1.1 Danaher Corporation
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2 Merck KGAA
8.1.2.1 Company overview
8.1.2.2 Financial Performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Parker Hannifin Corporation
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Sartorius AG
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5 Rad Source Technologies
8.1.5.1 Company overview
8.1.5.2 Product benchmarking
8.1.6 Viral Inactivated Plasma Systems SA
8.1.6.1 Company overview
8.1.6.2 Product benchmarking
8.1.7 Cerus Corporation
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.8 Clean Cells Inc.
8.1.8.1 Company overview
8.1.8.2 Product benchmarking
8.1.9 Texcell, Inc.
8.1.9.1 Company overview
8.1.9.2 Product benchmarking
8.1.10 Wuxi Pharmatech (Cayman) Inc.
8.1.10.1 Company overview
8.1.10.2 Product benchmarking
8.1.11 Charles River Laboratories
8.1.11.1 Company overview
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives
8.1.12 BioReliance
8.1.12.1 Company overview
8.1.12.2 Product benchmarking
8.1.12.3 Strategic initiatives
8.2 List of market players
LIST OF TABLES
TABLE 1 Factors used in segment share estimation
TABLE 2 List of secondary data sources
TABLE 3 North America viral inactivation market, by country, 2014 - 2025 (USD Million)
TABLE 4 North America viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 5 North America viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 6 North America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 7 U.S. viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 8 U.S. viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 9 U.S. viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 10 Canada viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 11 Canada viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 12 Canada viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 13 Europe viral inactivation market, by country, 2014 - 2025 (USD Million)
TABLE 14 Europe viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 15 Europe viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 16 Europe viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 17 Germany viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 18 Germany viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 19 Germany viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 20 UK viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 21 UK viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 22 UK viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 23 France viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 24 France viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 25 France viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 26 Italy viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 27 Italy viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 28 Italy viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 29 Spain viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 30 Spain viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 31 Spain viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 32 Asia Pacific viral inactivation market, by country, 2014 - 2025 (USD Million)
TABLE 33 Asia Pacific viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 34 Asia Pacific viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 35 Asia Pacific viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 36 Japan viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 37 Japan viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 38 Japan viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 39 China viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 40 China viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 41 China viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 42 India viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 43 India viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 44 India viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 45 Latin America viral inactivation market, by country, 2014 - 2025 (USD Million)
TABLE 46 Latin America viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 47 Latin America viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 48 Latin America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 49 Brazil viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 50 Brazil viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 51 Brazil viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 52 Mexico viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 53 Mexico viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 54 Mexico viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 55 MEA viral inactivation market, by country, 2014 - 2025 (USD Million)
TABLE 56 MEA viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 57 MEA viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 58 MEA viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 59 South Africa viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 60 South Africa viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 61 South Africa viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 62 Saudi Arabia viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 63 Saudi Arabia viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 64 Saudi Arabia viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 1 Factors used in segment share estimation
TABLE 2 List of secondary data sources
TABLE 3 North America viral inactivation market, by country, 2014 - 2025 (USD Million)
TABLE 4 North America viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 5 North America viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 6 North America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 7 U.S. viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 8 U.S. viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 9 U.S. viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 10 Canada viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 11 Canada viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 12 Canada viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 13 Europe viral inactivation market, by country, 2014 - 2025 (USD Million)
TABLE 14 Europe viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 15 Europe viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 16 Europe viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 17 Germany viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 18 Germany viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 19 Germany viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 20 UK viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 21 UK viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 22 UK viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 23 France viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 24 France viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 25 France viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 26 Italy viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 27 Italy viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 28 Italy viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 29 Spain viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 30 Spain viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 31 Spain viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 32 Asia Pacific viral inactivation market, by country, 2014 - 2025 (USD Million)
TABLE 33 Asia Pacific viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 34 Asia Pacific viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 35 Asia Pacific viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 36 Japan viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 37 Japan viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 38 Japan viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 39 China viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 40 China viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 41 China viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 42 India viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 43 India viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 44 India viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 45 Latin America viral inactivation market, by country, 2014 - 2025 (USD Million)
TABLE 46 Latin America viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 47 Latin America viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 48 Latin America viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 49 Brazil viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 50 Brazil viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 51 Brazil viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 52 Mexico viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 53 Mexico viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 54 Mexico viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 55 MEA viral inactivation market, by country, 2014 - 2025 (USD Million)
TABLE 56 MEA viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 57 MEA viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 58 MEA viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 59 South Africa viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 60 South Africa viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 61 South Africa viral inactivation market, by end-use, 2014 - 2025 (USD Million)
TABLE 62 Saudi Arabia viral inactivation market, by product, 2014 - 2025 (USD Million)
TABLE 63 Saudi Arabia viral inactivation market, by application, 2014 - 2025 (USD Million)
TABLE 64 Saudi Arabia viral inactivation market, by end-use, 2014 - 2025 (USD Million)
LIST OF FIGURES
FIG. 1 Primary interviews, by sources
FIG. 2 Primary interviews, by region
FIG. 3 Market summary (USD Million)
FIG. 4 Market trends & outlook
FIG. 5 Market segmentation & scope
FIG. 6 Market driver relevance analysis (Current & future impact)
FIG. 7 FDA Drug Approvals, 2015 - 2017
FIG. 8 Diabetes Prevalence, 2015 & 2040
FIG. 9 Market restraint relevance analysis (Current & future impact)
FIG. 10 Key opportunities prioritized, by product
FIG. 11 Key opportunities prioritized, by application
FIG. 12 Key opportunities prioritized, by end-use
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Company market position analysis, 2016
FIG. 16 Viral inactivation market, product outlook: Key takeaways
FIG. 17 Viral inactivation market: Product movement analysis
FIG. 18 Kits and Reagents market, 2014 - 2025 (USD Million)
FIG. 19 Systems market, 2014 - 2025 (USD Million)
FIG. 20 Services market, 2014 - 2025 (USD Million)
FIG. 21 Viral inactivation market, Application outlook: Key takeaways
FIG. 22 Viral inactivation market: Type movement analysis
FIG. 23 Vaccines and therapeutics market, 2014 - 2025 (USD Million)
FIG. 24 Stem cell products market, 2014 - 2025 (USD Million)
FIG. 25 Blood and blood products market, 2014 - 2025 (USD Million)
FIG. 26 Tissue and tissue products market, 2014 - 2025 (USD Million)
FIG. 27 Cellular and gene therapy market, 2014 - 2025 (USD Million)
FIG. 28 Viral inactivation market, end-use outlook: Key takeaways
FIG. 29 Viral inactivation market: End-use movement analysis
FIG. 30 Pharmaceutical and biopharmaceutical companies market, 2014 - 2025 (USD Million)
FIG. 31 CROs market, 2014 - 2025 (USD Million)
FIG. 32 Academic and research institutes market, 2014 - 2025 (USD Million)
FIG. 33 Others market, 2014 - 2025 (USD Million)
FIG. 34 Regional market place: Key takeaways
FIG. 35 Regional outlook, 2016 & 2025
FIG. 1 Primary interviews, by sources
FIG. 2 Primary interviews, by region
FIG. 3 Market summary (USD Million)
FIG. 4 Market trends & outlook
FIG. 5 Market segmentation & scope
FIG. 6 Market driver relevance analysis (Current & future impact)
FIG. 7 FDA Drug Approvals, 2015 - 2017
FIG. 8 Diabetes Prevalence, 2015 & 2040
FIG. 9 Market restraint relevance analysis (Current & future impact)
FIG. 10 Key opportunities prioritized, by product
FIG. 11 Key opportunities prioritized, by application
FIG. 12 Key opportunities prioritized, by end-use
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Company market position analysis, 2016
FIG. 16 Viral inactivation market, product outlook: Key takeaways
FIG. 17 Viral inactivation market: Product movement analysis
FIG. 18 Kits and Reagents market, 2014 - 2025 (USD Million)
FIG. 19 Systems market, 2014 - 2025 (USD Million)
FIG. 20 Services market, 2014 - 2025 (USD Million)
FIG. 21 Viral inactivation market, Application outlook: Key takeaways
FIG. 22 Viral inactivation market: Type movement analysis
FIG. 23 Vaccines and therapeutics market, 2014 - 2025 (USD Million)
FIG. 24 Stem cell products market, 2014 - 2025 (USD Million)
FIG. 25 Blood and blood products market, 2014 - 2025 (USD Million)
FIG. 26 Tissue and tissue products market, 2014 - 2025 (USD Million)
FIG. 27 Cellular and gene therapy market, 2014 - 2025 (USD Million)
FIG. 28 Viral inactivation market, end-use outlook: Key takeaways
FIG. 29 Viral inactivation market: End-use movement analysis
FIG. 30 Pharmaceutical and biopharmaceutical companies market, 2014 - 2025 (USD Million)
FIG. 31 CROs market, 2014 - 2025 (USD Million)
FIG. 32 Academic and research institutes market, 2014 - 2025 (USD Million)
FIG. 33 Others market, 2014 - 2025 (USD Million)
FIG. 34 Regional market place: Key takeaways
FIG. 35 Regional outlook, 2016 & 2025
